Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) rose by 7.71%. The shares opened at a price of $63.99, which touched the intraday high of $70.17 and headed to a close of $69.29. Around 4.86 million exchanged hands over the trading day and an average volume of 2.14 million shares were traded over a 30 day period. The 52-week low of BioMarin Pharmaceutical Inc (NASDAQ:BMRN) shares is $46.53 and its 52-week high is $80.67. The company has a market capitalization of $9.85 billion.
About the company
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) was incorporated on 25 October, 1996. The company develops & commercializes pharmaceuticals that are used for the treatment of serious diseases & medical conditions. Its product portfolio is made up of 4 approved products & multiple investigational-product candidates. The Approved-products include Naglazyme, Kuvan, Aldurazyme & Firdapse (amifampridine phosphate). BioMarin Pharmaceutical Inc (NASDAQ:BMRN) is conducting different clinical trials on various product candidates for treating various diseases. This includes Vimizim which was previously referred to as GALNS. This is an enzyme-replacement therapy that is used to treat Mucopolysaccharidosis Type IV / Morquio Syndrome Type A , PEG-PAL, the enzyme-substitution therapy for treating phenylketonuria (PKU), BMN-701, the enzyme-replacement therapy for the Pompe disease, a glycogen-storage disorder.
The company also has under trial another drug candidate, BMN-673. This is an orally available poly-polymerase, or PARP-inhibitor that is used to treat certain cancers& BMN-111, which is a peptide-therapeutic for treating achondroplasia. On 7 January, 2013, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) acquired Zacharon Pharmaceuticals.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN is conducting / planning on conducting preclinical-development of various other enzyme-product candidates for genetic & other metabolic-diseases, such as BMN-190 for treating late infantile-neuronal ceroid lipofuscinosis. This is a kind of Batten disease. BioMarin Pharmaceutical Inc (NASDAQ:BMRN) is developing Vimizim- this is an enzyme replacement therapy for treating MPS IV A, which is a lysosomal-storage disorder.